Vacation Week: Limited Postings…Updates 8/18 GILD XLV

http://moneyrebound.com/should-i-save-or-invest-my-money/ Biotech Weekly Ending 8/18 …Five Day Performance The Biotech sector held on a turbulent geopolitical week favoring large caps. Amgen (AMGN) up 1.7%, Merck (MRK) up 3.6%, Regeneron (REGN) up 2.1%. Gilead Sciences (GILD) was off 6% on concerns it would lose market share of its HIV drug to GlaxoSmith Kline (GSK) up 2.9% for […]

Continue Reading 0

Biotech Snapshot During a Rally Day: No Summer Doldrums…Updates

http://araliasystems.com/wp-content/themes/igora/js/ photo.link Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%,  XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug […]

Continue Reading 0

Rayno Biopharma Portfolio 2018 YTD: Performance Summary

online prescription Deltasone Rayno Biopharma Performance 2018: YTD 8/4 Large Caps Begin to Outperform FBT Is the Best All Around Life Science Play We have provided herein a summary of biopharma portfolio positions for our readers. The Rayno portfolio picks are designed for long-term performance and does not include short-term high volatility trades. The best way to make money […]

Continue Reading 0

Q2 Earnings Update: bluebird bio (BLUE) and Regeneron (REGN)

Q2 Earnings Updates: BLUE,REGN Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. U.S.Eyelea sales grew 8% to$992M and global sales grew 13% to $1.66B.  Eczema drug Dupixent grew to $209M. Regeneron (REGN) recently hit its low for the year just this past May below $300! Back in early […]

Continue Reading 0

Rayno BioBeat #5: July 2018 Mid-Cap Momentum Fades With Rotation Into Large Caps-Healthcare Stocks Are Strong (XLV)…Updates

aspirin 325 mg bid Aug 1 Update…overall a good day Hot Mid-Caps: BPMC up 12.18%, NBIX up 13%, SRPT up 3.47% Large Cap Rayno Portfolio Movers: ABBV up 1.82%,  BIIB up 2.9%, BMY up 1.48% XLV Flat today after 6.2% run in July, FBIOX up 1.7% with LOXO,NBIX added ============= Momentum Faded Since Strong ASCO Rally Rotation into Large […]

Continue Reading 0

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotechs Hold and Ignore Rocky Week of Global Politics- Big Earnings Upcoming…Updates CELG, BIIB, AZN, XBI

7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9%  to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock drops 10% to $344.75 as […]

Continue Reading 0

Biotechs Cruise onto Green Screen: July Looks Good…Updates

Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck succumbs to Trump pricing pressure with a minor Hep-C drug. Mid-caps mainly green, large caps […]

Continue Reading 0

Biotech Rally Buffeted By Trump Tweet But Gains Hold…Update-2

Update-2 …Futures Sink As Trade War Rhetoric Heats Up: China Responds to Trump Additional $200B in tariffs on Chinese goods that may get hit with tariffs-See Bloomberg updates. China will take countermeasures-strongly opposed US action. Nikkei hit hardest down 2.1%. China commerce ministry official says US tariff plan hurts WTO system. ============= Update-1… Biotech Stocks […]

Continue Reading 0

Biotech Momentum Is Boosted by Biogen’s Alzheimer Disease Drug Results

Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting  Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late June. Rally is just short of hitting new 2018 highs in the sector. Biotech stocks  rallied with […]

Continue Reading 0